Physician profile
Tiffany Andrzejewski
NPI 1174836548
$28,939.11
in general payments reported to CMS, 2019-2025
28 companies · $4,390 in 2025
The $4,390 reported for 2025 was more than what 96% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $1,977 · 2021: $5,910 · 2022: $1,185 · 2023: $1,721 · 2024: $13K · 2025: $4,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,840 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,650 · Food and Beverage: $3,297 · Travel and Lodging: $2,852 · Consulting Fee: $1,150 · Gift: $350 · Entertainment: $38.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,840.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,650.00 |
| Food and Beverage | $3,297.00 |
| Travel and Lodging | $2,851.97 |
| Consulting Fee | $1,150.00 |
| Gift | $350.00 |
| Entertainment | $38.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $10,779.77 | 2022-2025 | Synergeyes Contact Lens, Onefit Contact Lens, Rose K Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $7,200.61 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $6,225.83 | 2022-2025 | Zenlens, Miebo, Vyzulta |
| Glaukos Corporation | $828.03 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Visionary Optics LLC | $669.96 | 2023 | |
| Ocular Therapeutix, INC. | $637.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $630.04 | 2019-2023 | |
| Beaver-Visitec International, INC. | $387.15 | 2022-2023 | |
| Alcon Vision LLC | $363.04 | 2020-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $190.24 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $160.28 | 2024-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $92.25 | 2022-2023 | Acthar |
| Allergan, INC. | $89.44 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $89.02 | 2020-2021 | |
| Oyster Point Pharma, INC. | $71.95 | 2022-2024 | Tyrvaya, Ryzumvi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $71.65 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $60.34 | 2021-2022 | |
| Abbvie INC. | $60.31 | 2024-2025 | |
| Eyevance Pharmaceuticals LLC | $57.64 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $53.78 | 2023-2025 | Acuvue |
| Synergeyes, INC. | $45.00 | 2020 | |
| Aerie Pharmaceuticals, INC. | $39.65 | 2021 | |
| Optos, INC. | $38.92 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $22.65 | 2019 | |
| Thea Pharma INC. | $20.62 | 2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.39 | 2022 | |
| Dompe US, INC. | $15.82 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Andrzejewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.